SLC5A2 and type 2 diabetes mellitus: Proximal tubular SGLT2 inhibitors are anti-hyperglycemic agents that reduce ROS production and help preserve the renal and cardiac function of hypertensive patients, regardless of their type 2 diabetes status [381].